Stryker (NYSE:SYK) Given New $358.00 Price Target at BTIG Research

Posted by Brenda Bartman on Aug 1st, 2026

Stryker (NYSE:SYK – Free Report) had its target price lowered by BTIG Research from $371.00 to $358.00 in a report issued on Friday morning, MarketBeat.com reports. The brokerage currently has a buy rating on the medical technology company’s stock.

SYK has been the topic of several other reports. Barclays dropped their price target on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. BMO Capital Markets assumed coverage on shares of Stryker in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price objective for the company. Robert W. Baird set a $385.00 price objective on shares of Stryker in a research note on Friday, May 1st. Evercore set a $350.00 target price on shares of Stryker in a report on Monday, July 6th. Finally, Argus set a $370.00 target price on shares of Stryker in a research note on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $387.88.

View Our Latest Analysis on Stryker

Stryker Stock Down 6.2%

NYSE:SYK opened at $326.41 on Friday. Stryker has a twelve month low of $281.00 and a twelve month high of $401.99. The firm has a market capitalization of $125.13 billion, a price-to-earnings ratio of 33.82, a price-to-earnings-growth ratio of 2.23 and a beta of 0.77. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The stock’s 50 day moving average price is $317.28 and its two-hundred day moving average price is $334.92.

Stryker (NYSE:SYK – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 24.06% and a net margin of 14.43%.The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter in the prior year, the firm posted $3.13 EPS. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts expect that Stryker will post 14.99 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Insiders Place Their Bets

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares in the company, valued at $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 323,264 shares of company stock valued at $100,659,489 over the last ninety days. 4.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of SYK. Tema ETFs LLC raised its holdings in Stryker by 31.3% in the 2nd quarter. Tema ETFs LLC now owns 7,306 shares of the medical technology company’s stock valued at $2,300,000 after acquiring an additional 1,743 shares during the period. Dagco Inc. boosted its holdings in shares of Stryker by 24.0% during the second quarter. Dagco Inc. now owns 1,133 shares of the medical technology company’s stock worth $357,000 after acquiring an additional 219 shares during the period. Lederer & Associates Investment Counsel CA boosted its holdings in shares of Stryker by 8.9% during the second quarter. Lederer & Associates Investment Counsel CA now owns 5,398 shares of the medical technology company’s stock worth $1,700,000 after acquiring an additional 442 shares during the period. E. Ohman J or Asset Management AB grew its position in shares of Stryker by 1,008.0% in the second quarter. E. Ohman J or Asset Management AB now owns 131,471 shares of the medical technology company’s stock valued at $41,392,000 after purchasing an additional 119,605 shares during the last quarter. Finally, LVM Capital Management Ltd. MI grew its position in shares of Stryker by 15.9% in the second quarter. LVM Capital Management Ltd. MI now owns 62,584 shares of the medical technology company’s stock valued at $19,704,000 after purchasing an additional 8,576 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

Positive Sentiment: Stryker reported second-quarter revenue of $6.59 billion, up 9.4% year over year, while adjusted EPS of $3.69 exceeded consensus estimates. Organic sales growth reached 9%, supported by strong demand for orthopedic, spinal and other medical devices. Stryker beats quarterly estimates on strong demand for medical devices
Positive Sentiment: Management said it has regained momentum following the cyber disruption and resumed share repurchases. Its full-year guidance calls for 8.3% to 9.3% organic sales growth and adjusted EPS of $14.95 to $15.10. Stryker expects 2026 organic sales growth and adjusted EPS
Positive Sentiment: JPMorgan maintained an “overweight” rating, although it reduced its price target to $350. Truist raised its target to $340 while retaining a “hold” rating, and BTIG continues to rate the shares “buy.”
Neutral Sentiment: The updated guidance was narrower but remained broadly close to prior expectations and analyst forecasts. This suggests operational stability, but not a major upside revision that could drive a stronger investor reaction.
Neutral Sentiment: Analyst opinion remains generally constructive, with no recent sell ratings cited and a six-month median price target of $385, though target reductions indicate some caution regarding valuation or near-term upside.
Negative Sentiment: The main pressure on SYK appears to be an expectations reset: despite the earnings beat, investors had anticipated a more substantial increase to full-year guidance after the cyberattack recovery. SYK falls despite Q2 earnings beat
Negative Sentiment: Reported insider activity has been heavily weighted toward selling, with no purchases and substantial sales over the past six months. This may add to investor concerns about valuation and management confidence, although the trades do not necessarily reflect current operating performance.

About Stryker

(Get Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.